Human immunodeficiency virus type 1 attachment, coreceptor, and fusion inhibitors are active against both direct and trans infection of primary cells (PDF)
Ketas,Thomas J.; Frank,Ines; Klasse,Per Johan; Sullivan,Brian M.; Gardener,Jason P.; Spenlehauer,Catherine; Nesin,Mirjana; Olson,William C.; Moore,John P.; Pope,Melissa
Journal of Virology 77(4): 2762-2767
Publication date: 2003
Inhibitors of human immunodeficiency virus type 1 attachment (CD4-immunoglobulin G subclass 2), CCR5 usage (PRO 140), and fusion (T-20) were tested on diverse primary cell types that represent the major targets both for infection in vivo and for the inhibition of trans infection of target cells by virus bound to dendritic cells. Although minor cell-type-dependent differences in potency were observed, each inhibitor was active on each cell type and trans infection was similarly vulnerable to inhibition at each stage of the fusion cascade.
For 60 years, the Population Council has changed the way the world thinks about important health and development issues. Explore an interactive timeline of the Council's history, learn more about some of our key contributions, and watch a short video about why your support is so important to us.